Immuno Oncology Summit US 2025

Fusion Representatives will be attending the 13th Annual Immuno-Oncology Summit which showcases successes in preclinical and clinical studies grounded in a deep understanding of biology. Coverage spans solid tumor innovations, including bi/multispecific antibodies, antibody-drug conjugates (ADCs), allogenic and in vivo CAR-Ts, TILs, TCRs, Tregs, multiple cell therapies working together, the tumor microenvironment, innate immunity, gamma delta T cells, NK cells, organoid modeling, data science, and machine learning.

We will be presenting Posters on our Revolutionary OptiMAL™ Platform for the discovery of novel antibodies using Mammalian Display on a naïve human library designed by Fusion & our Rational In-silico Developability platform (Ab-ility™) for both in-depth sequence analysis, 3-D modelling and liability engineering alongside rapid sequence screening built for lead selection.

About Fusion Antibodies

Fusion Antibodies is an end-to-end antibody discovery partner offering a range of services in antibody generation, development, production, characterisation, and optimisation.

We have guided hundreds of projects through critical pre-clinical stages, repeatedly proving our expertise as we strive to bring about a positive change in the healthcare industry. 

If you would like to set up a meeting to discuss our capabilities or to find out more about how we can advance your project to the next stage, please contact us here.